Jenny Jing Xiang, MD, on Improving Clinical Trial Recruitment With a Universal Prescreening Protocol
2021 ASCO Quality Care Symposium
Jenny Jing Xiang, MD, of Yale University School of Medicine, discusses a universal, standardized clinical trial prescreening protocol, which streamlined research recruitment and was associated with yearly increases in patient enrollment at the Veterans Administration (VA) Connecticut Cancer Center. The Center became the top-accruing VA site for National Cancer Institute–sponsored trials and was ranked in the top 10 enrolling sites nationally for VA and non-VA hospitals.
The ASCO Post Staff
Morgan R.L. Lichtenstein, MD, of Columbia University Medical Center, discusses a single-center prospective study examining the complex relationship between time to oral oncolytic receipt and clinical or process-related factors, such as prior authorization, diagnosis, and insurance type.
The ASCO Post Staff
Katherine E. Reeder-Hayes, MD, MBA, of the University of North Carolina at Chapel Hill, discusses the timeliness of breast cancer care for Black women compared with non-Black women in North Carolina. Her data showed that greater geographic variation exists in the timeliness of breast cancer care for Black women, with regions surrounding larger urban centers having the largest disparities.
The ASCO Post Staff
Sarah S. Mougalian, MD, of Yale Cancer Center, discusses the increasingly common problem of long wait times for access to oncology care. Her team developed a next-day access program in several of Yale’s oncology services, which was well received by patients and decreased the time to first visit.
The ASCO Post Staff
Divya A. Parikh, MD, of Stanford University School of Medicine, discusses findings that suggest an evidence-based tool, the Serious Illness Conversation Guide, may engage patients with metastatic or recurrent urologic cancer in goals-of-care conversations, potentially resulting in an increase of documentation of their goals in the electronic medical record.
The ASCO Post Staff
Aakash Desai, MPH, MD, of the Mayo Clinic in Rochester, Minnesota, talks about the urgent need for drug pricing reform, given the average expenditure of Medicare part D, and the ultimate out-of-pocket costs for patients with cancer. The promise of precision oncology will fail, says Dr. Desai, if we fail to bring the right drugs to the right patient at the right time, with the right price.
